Table 1. Baseline characteristics.
| Characteristic | Number (percentage where applicable) |
|---|---|
| Median age (years) | 54 (range, 22–79) |
| Gender | |
| Male | 59 (65.6) |
| Female | 31 (34.4) |
| Stage | |
| Localized, operable | 28 (31.1) |
| Locally advanced | 36 (40) |
| Metastatic | 26 (28.9) |
| Site | |
| Gastric | 37 (41.1) |
| Jejunum | 20 (22.2) |
| Duodenum | 07 (7.7) |
| Ileum | 06 (6.6) |
| Colon | 01 (1.1) |
| Rectum | 07(7.7) |
| Retroperitoneal | 05 (5.5) |
| Mesenteric | 04 (4.4) |
| Others | 02 (2.2) |
| Radical Surgery | |
| Yes | 63 (70) |
| Localized operable (n=28) | 28 (100) |
| Locally advanced (n=36) | 26 (72.2) |
| Metastatic (n=26) | 09 (34.6) |
| No | 27 (30) |
| Resection status (n=63) | |
| R0 | 59 (93.6) |
| R+ | 4 (6.4) |
| Locally advanced (n=36) | |
| Neoadjuvant IM | 30 |
| Adjuvant IM | 23 |
| Median duration of neoadjuvant IM (months) | 7.5 |
| Median duration of adjuvant IM (months) | 27 |
| Localized operable (n=28) | |
| Median duration of adjuvant IM (months) | 27 |
IM, Imatinib mesylate.